Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15


Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.

Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM.

Cancer. 2019 Oct 18. doi: 10.1002/cncr.32539. [Epub ahead of print]


Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma.

Haque SU, Niu L, Kuhnell D, Hendershot J, Biesiada J, Niu W, Hagan MC, Kelsey KT, Casper KA, Wise-Draper TM, Medvedovic M, Langevin SM.

Head Neck. 2018 Jul;40(7):1555-1564. doi: 10.1002/hed.25136. Epub 2018 Mar 25.


A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC.

Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9.


Oncolytic virotherapy for head and neck cancer: current research and future developments.

Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM.

Oncolytic Virother. 2015 Jul 20;4:83-93. doi: 10.2147/OV.S54503. eCollection 2015. Review.


Human papillomavirus induced transformation in cervical and head and neck cancers.

Adams AK, Wise-Draper TM, Wells SI.

Cancers (Basel). 2014 Sep 15;6(3):1793-820. doi: 10.3390/cancers6031793. Review.


DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.

Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison ML, Wikenheiser-Brokamp KA, Wise-Draper TM, Wells SI.

Oncogene. 2015 Feb 12;34(7):868-77. doi: 10.1038/onc.2014.15. Epub 2014 Mar 10.


A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.

Eur J Cancer. 2013 Jul;49(10):2345-55. doi: 10.1016/j.ejca.2013.03.005. Epub 2013 Apr 8.


Future directions and treatment strategies for head and neck squamous cell carcinomas.

Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI.

Transl Res. 2012 Sep;160(3):167-77. doi: 10.1016/j.trsl.2012.02.002. Epub 2012 Feb 28.


The human DEK oncogene regulates DNA damage response signaling and repair.

Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmüller L, Wells SI.

Nucleic Acids Res. 2011 Sep 1;39(17):7465-76. doi: 10.1093/nar/gkr454. Epub 2011 Jun 7.


Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI.

Cancer Res. 2009 Mar 1;69(5):1792-9. doi: 10.1158/0008-5472.CAN-08-2304. Epub 2009 Feb 17.


DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI.

Am J Pathol. 2009 Jan;174(1):71-81. doi: 10.2353/ajpath.2009.080330. Epub 2008 Nov 26.


Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.

Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, Wells SI.

Oncogene. 2008 Aug 14;27(35):4798-808. doi: 10.1038/onc.2008.121. Epub 2008 Apr 28.


Papillomavirus E6 and E7 proteins and their cellular targets.

Wise-Draper TM, Wells SI.

Front Biosci. 2008 Jan 1;13:1003-17. Review.


Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI.

Mol Cell Biol. 2006 Oct;26(20):7506-19. Epub 2006 Aug 7.


The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.

Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K, Wells SI.

J Virol. 2005 Nov;79(22):14309-17.

Supplemental Content

Loading ...
Support Center